Abstract

Aim: Epilepsy frequently accompanies neurocutaneous syndromes. Due to the comorbid conditions that epileptic seizures may cause, their frequency, type, and duration also affect the prognosis of neurocutaneous diseases. The purpose of this study was to examine the frequency of epilepsy and drug-resistant epilepsy in neurocutaneous syndromes, and factors affecting the development of drug-resistant epilepsy.

Methods: In our clinic, nine of the 24 patients who were under follow-up due to neurocutaneous syndromes were diagnosed with Tuberous Sclerosis Complex (TSC), six with Sturge-Weber syndrome, and nine with Neurofibromatosis type 1. We examined the age at diagnosis, findings at the time of the diagnosis, the presence of accompanying epilepsy, age at onset of seizures, seizure type and frequency, antiepileptic drugs used, responses to antiepileptic drugs, electroencephalography and brain magnetic resonance imaging findings, neurological-neuro-ophthalmological and physical examination results, and systemic findings.

Results: Age at onset of seizures ranged between four months and four years. A pre-diagnosis history of seizure was present in all the patients with TSC, and the first seizure in 55% of the patients was epileptic spasm type. Hemiparesis and port wine stain were present at the time of diagnosis in Sturge-Weber syndrome, while accompanying seizures were observed later.

Conclusion: The frequency of accompanying epilepsy and drug-resistant epilepsy is higher in the TSC.

Keywords: Drug-resistant epilepsy, epilepsy, neurocutaneous syndromes

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Danış A, Hancı F. Epilepsy and drug-resistant epilepsy in neurocutaneous syndromes. Northwestern Med J. 2023;3(1):50-5. https://doi.org/10.54307/NWMJ.2023.77486

References

  1. Cross JH. Neurocutaneous syndromes and epilepsy-issues in diagnosis and management. Epilepsia. 2005; 46 Suppl 10: 17-23. https://doi.org/10.1111/j.1528-1167.2005.00353.x
  2. Diaconu G, Grigore I, Burlea M, Chirakis N, Lupu VV. Neurocutaneous syndromes and epilepsy. Report of 23 cases and review of the literature. Rev Med Chir Soc Med Nat Iasi. 2004; 108(3): 575-9.
  3. Jansen FE, Vincken KL, Algra A, et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology. 2008; 70(12): 916-23. https://doi.org/10.1212/01.wnl.0000280579.04974.c0
  4. Jeste SS, Varcin KJ, Hellemann GS, et al. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. Neurology. 2016; 87(8): 766-72. https://doi.org/10.1212/wnl.0000000000003002
  5. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010; 14(2): 146-9. https://doi.org/10.1016/j.ejpn.2009.03.003
  6. Davis PE, Kapur K, Filip-Dhima R, et al. Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. Epilepsia. 2019; 60(8): 1721-32. https://doi.org/10.1111/epi.16284
  7. Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA. Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia. 2009; 50(2): 290-6. https://doi.org/10.1111/j.1528-1167.2008.01788.x
  8. Wu JY, Peters JM, Goyal M, et al. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016; 54: 29-34. https://doi.org/10.1016/j.pediatrneurol.2015.09.013
  9. Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol. 2015; 52(3): 281-9. https://doi.org/10.1016/j.pediatrneurol.2014.10.028
  10. Im K, Ahtam B, Haehn D, et al. Altered Structural Brain Networks in Tuberous Sclerosis Complex. Cereb Cortex. 2016; 26(5): 2046-58. https://doi.org/10.1093/cercor/bhv026
  11. Wu JY, Goyal M, Peters JM, et al. Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study. Epilepsia. 2019; 60(12): 2428-36. https://doi.org/10.1111/epi.16379
  12. Kossoff EH, Hatfield LA, Ball KL, Comi AM. Comorbidity of epilepsy and headache in patients with Sturge-Weber syndrome. J Child Neurol. 2005; 20(8): 678-82. https://doi.org/10.1177/08830738050200080901
  13. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013; 49(4): 243-54. https://doi.org/10.1016/j.pediatrneurol.2013.08.001
  14. Barba C, Jacques T, Kahane P, et al. Epilepsy surgery in Neurofibromatosis Type 1. Epilepsy Res. 2013; 105(3): 384-95. https://doi.org/10.1016/j.eplepsyres.2013.02.021
  15. Kulkantrakorn K, Geller TJ. Seizures in neurofibromatosis 1. Pediatr Neurol. 1998; 19(5): 347-50. https://doi.org/10.1016/s0887-8994(98)00075-7
  16. Erdal A, Demir AB, Midi İ, et al. Neurocutaneous syndromes and epilepsy. Epilepsi. 2016; 22(1): 12-6. https://doi.org/10.5505/epilepsi.2016.63634